IQVIA OMOP conducted a patient-level prediction study across U.S. and European databases to classify T2DM patients likely to become high-cost. Using gradient boosting models and SHAP analysis, predictors included high HbA1c, comorbidities (e.g., ASCVD, heart failure), BMI ≥ 40, lifestyle factors, and historical resource use. Results revealed heterogeneity across regions but consistently linked poor glycemic control with higher costs. Insights helped the client design future clinical trials and support payer discussions on earlier intervention strategies, highlighting real-world cost-saving potential.

Join for free to read